Teva Pharmaceuticals has announced the launch of an authorized generic version of Victoza® (liraglutide injection) in the United States. This marks the first generic GLP-1 receptor agonist available, a significant milestone for diabetes treatment. Liraglutide is a GLP-1 receptor agonist commonly used for type 2 diabetes management, offering substantial benefits including improved glycemic control and potential weight loss. The launch aims to increase accessibility for patients requiring liraglutide by providing a more affordable option compared to the branded version.

For more information, visit Teva Pharmaceuticals.